The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease

Mitochondrial Myopathy Clinical Trial

Official title:

Exercise Training and Deconditions: Implications for Therapy in Mitochondrial Myopathy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00457314
• Other study ID #: R01AR050597
• Secondary ID: 1R01AR050597-01A
• Status: Recruiting
• Phase: Phase 2
• First received: April 5, 2007
• Last updated: May 18, 2009
• Start date: June 2007
• Est. completion date: June 2012

Study information

• Verified date: May 2009
• Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• Contact: Ronald Haller, MD
• Phone: 214-345-4621
• Email: rhaller2[@]earthlink.net
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

Mitochondrial myopathies include various inherited diseases that are caused by damage to the mitochondria, energy-producing structures that fuel the body's processes. The main symptoms are muscle weakness, reduced muscle mass, and difficulty with exercising. The purpose of this study is to determine the effects of exercise training versus inactivity on mitochondrial function in muscle and muscle performance in people with mitochondrial myopathies.

Description:

Mitochondrial myopathies are caused by mutant mitochondrial DNA, genetic defects in parts of the mitochondrial DNA. These defects can include missing or deleted DNA that typically codes for certain proteins involved in energy production. These mutations cause individual mitochondria and the body on a whole to produce energy less efficiently. Because muscle cells require extensive energy to function properly, they are particularly impaired by mitochondrial dysfunction. The onset of most mitochondrial myopathies occurs before the age of 20. Initially a person may experience muscle weakness and fatigue during physical activity. Other symptoms may include limited eye mobility, heart arrhythmias, slurred speech, swallowing difficulties, and impaired movement.

There is no cure yet for mitochondrial myopathies, nor is there any adequate treatment to stall disease progression. Exercise, known to boost the production and function of mitochondria in healthy people, may reduce symptoms in people with mitochondrial myopathies by increasing the number and function of normal mitochondria in an individual muscle cell. The purpose of this study is to determine the effects of exercise training versus inactivity on the expression of normal and mutant mitochondrial DNA and on mitochondrial production within muscle cells in people with mitochondrial myopathies. The study will also assess how cell function, physical endurance, heart function, and quality of life are affected by exercise training and inactivity.

Participants in this 2-year study will first undergo physiological exercise testing, magnetic resonance imaging (MRI) of heart and skeletal muscles, a needle biopsy of muscle, and a questionnaire on quality of life. Participants will then be randomly assigned to partake in regular exercise training or no training for 6 months. After 6 months, all participants will undergo repeat testing of initial evaluations. Participants who had been in the exercising group will then switch to no exercise training for 6 months, and participants who had been in the non-exercising group will switch to regular exercise training for 6 months. The second 6-month period will also be followed by repeat testing of initial evaluations. Participants will then be encouraged to continue exercise training for an additional 1 year, with retesting at the end of the second year. Each of the four evaluations will take about 15 hours over 5 days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: June 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis of mitochondrial myopathy

• Single-large scale deletions of mitochondrial DNA

• Point mutations in mitochondrial DNA

Exclusion Criteria:

• Symptoms or electrocardiogram-generated signs of coronary artery disease

• Symptoms of congestive heart failure; peripheral vascular disease; or lung, kidney, or liver disease

• History of alcohol or substance abuse

• Metal implants or related devices that contraindicate MRI

• Current use of or require any medications that have significant systemic cardiovascular effects

• Diabetes

• Obesity (body mass index [BMI] greater than 30)

• Resting systolic blood pressure greater than 140 mmHg and/or diastolic blood pressure greater than 90 mmHg at three different times

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Mitochondrial Myopathies
• Mitochondrial Myopathy
• Muscular Diseases

Intervention

Behavioral:
• Exercise
Regular exercise training

Locations

Country	Name	City	State
United States	University of Texas Southwestern Medical Center	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in wild-type (normal), mutant, and total mitochondrial DNA copy number		Measured at Week 26	No
Primary	Physiological measure of oxidative metabolism		Measured at Week 26	No